Zevra Therapeutics Stock Sees Healthy RS Rating Jump To 73

Core Insights - Zevra Therapeutics (ZVRA) experienced a rise in its Relative Strength Rating from 62 to 73, indicating improved stock performance compared to peers [1] - The rating system used ranges from 1 (worst) to 99 (best), reflecting the stock's price action over the past 52 weeks [1] Company Performance - Following a significant increase of 89% in stock price, Zevra Therapeutics faced a crash attributed to market reactions regarding its acquired drug, Olpruva [2] - An analyst described the stock's decline as an "overreaction" to the issues surrounding Olpruva, suggesting potential for recovery [2]